
Opinion|Videos|June 18, 2024
HE Experts on Symptoms, Risk Factors, Diagnosis Challenges, and Severity Grading
The expert panelists explore the symptoms and risk factors associated with HE, the challenges in diagnosing the condition due to its resemblance to neuropsychiatric l disorders, and the methods used to assess and grade the severity of the disease.
Advertisement
Episodes in this series

Please describe the symptoms and risk factors associated with HE?
- Clinical diagnosis
- Approaches to diagnosis that are concordant with current guideline recommendations.
Please explain how HE is classified and why it matters? Also, how do we grade severity?Vilstrup et al 2014
- What is the distinction between covert and overt hepatic encephalopathy? Bellafante et al 2024
Advertisement
Related to this article

In a phase 2 decentralized study, once-daily trientine tetrahydrochloride improved convenience and adherence in Wilson disease; 80% preferred it.

Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.

In adults with late-onset PFIC, odevixibat improved pruritus within 3 months in a real-world study at presented at The Liver Meeting 2026.

CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.

In patients with compensated MASH cirrhosis, Baveno VII and ANTICIPATE-NASH showed moderate agreement with HVPG and underestimated CSPH prevalence.

Robert Mentz, MD, discusses mentorship, trial recruitment, journal growth, and surgical partnerships in heart failure care.

At GOLD 2026, Alvar AgustĂ, MD, PhD, speaks on COPD underdiagnosis and misdiagnosis, barriers to spirometry in primary care, and managing pre-COPD.
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
3
Conference Preview: 2026 GOLD International COPD Conference
4
ELSPIRE: Elafibranor Achieves ALP Normalization in 85% With PBC
5

